A controlled randomized trial of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000081

Enrollment

Unknown

Registered

2008-03-31

Start date

2004-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

TACE+thalidomide group:Patients take thalidomide 100 mg/d for 7 days after TACE and take thalidomide 200 mg/d in succession

TACE group:TACE alone

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with inoperable HCC diagnosed of HCC was based on high serum alpha-fetoprotein (AFP>=400ng/ml), ultrasonography, computed tomography (CT), or needle liver biopsy while AFP =60 and an anticipated life expectancy of at least 12 weeks. Patients were also required to be between 18 and 75 years of age.

Exclusion criteria

Exclusion criteria: Patients with active infections and have brain metastases or serious brain illness or mental illness; pregnancy or breast-feeding women; Patients participated in other clinical experiments in four weeks; double primary cancers; patients with a thrombotic diseases in an earlier time.

Design outcomes

Primary

Measure	Time frame
OS;TT;	—

Countries

China

Contacts

Public ContactMing-zhi Hao

haomzys@163.com+86 0 13067231562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026